Undifferentiated connective tissue disease medical therapy: Difference between revisions
Ahmed Younes (talk | contribs) No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as [[methotrexate]] in those exhibiting [[arthritis]] and [[dermatitis]]. Supportive therapy includes; avoiding cold exposure in those experiencing [[Raynaud's phenomenon]], avoiding sun in [[photosensitivity]], [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]] for pain control, [[sunscreen]] used for [[photosensitivity]], and [[emollients]] for dry skin | The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as [[methotrexate]] in those exhibiting [[arthritis]] and [[dermatitis]]. Supportive therapy includes; avoiding cold exposure in those experiencing [[Raynaud's phenomenon]], avoiding sun in [[photosensitivity]], [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]] for pain control, [[sunscreen]] used for [[photosensitivity]], and [[emollients]] for dry skin and rash. | ||
==Medical Therapy== | ==Medical Therapy== | ||
| Line 20: | Line 20: | ||
*Oral regimen | *Oral regimen | ||
**Preferred regimen (1): [[Methotrexate]] 7.5 mg PO q24h for 6 months '''(not used for CNS symptoms or serositis)'''<ref name="pmid8782131">{{cite journal |vauthors=Wise CM, Vuyyuru S, Roberts WN |title=Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients |journal=J. Rheumatol. |volume=23 |issue=6 |pages=1005–10 |date=June 1996 |pmid=8782131 |doi= |url=}}</ref> | **Preferred regimen (1): [[Methotrexate]] 7.5 mg PO q24h for 6 months '''(not used for CNS symptoms or serositis)'''<ref name="pmid8782131">{{cite journal |vauthors=Wise CM, Vuyyuru S, Roberts WN |title=Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients |journal=J. Rheumatol. |volume=23 |issue=6 |pages=1005–10 |date=June 1996 |pmid=8782131 |doi= |url=}}</ref> | ||
*** Dose | *** Dose can be gradually increased to 13.6 mg after 6 months | ||
==References== | ==References== | ||
Latest revision as of 18:30, 30 May 2018
|
Undifferentiated connective tissue disease Microchapters |
|
Differentiating Undifferentiated connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Undifferentiated connective tissue disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Undifferentiated connective tissue disease medical therapy |
|
FDA on Undifferentiated connective tissue disease medical therapy |
|
CDC on Undifferentiated connective tissue disease medical therapy |
|
Undifferentiated connective tissue disease medical therapy in the news |
|
Blogs on Undifferentiated connective tissue disease medical therapy |
|
Directions to Hospitals Treating Undifferentiated connective tissue disease |
|
Risk calculators and risk factors for Undifferentiated connective tissue disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as methotrexate in those exhibiting arthritis and dermatitis. Supportive therapy includes; avoiding cold exposure in those experiencing Raynaud's phenomenon, avoiding sun in photosensitivity, non-steroidal anti-inflammatory drugs for pain control, sunscreen used for photosensitivity, and emollients for dry skin and rash.
Medical Therapy
Routine measures
- Avoiding cold exposure in those experiencing Raynaud's phenomenon
- Avoiding sun in photosensitivity
Supportive therapy
- Non-steroidal anti-inflammatory drugs for pain control
- Sunscreen used for photosensitivity
- Emollients for dry skin, rash
Arthritis and dermatitis
- Oral regimen
- Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)[1]
- Dose can be gradually increased to 13.6 mg after 6 months
- Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)[1]